Intranasal infusion of GD3 and GM1 gangliosides downregulates alpha-synuclein and controls tyrosine hydroxylase gene in a PD model mouse

Parkinson’s disease (PD) is characterized by Lewy bodies (composed predominantly of alpha-synuclein [aSyn]) and loss of pigmented midbrain dopaminergic neurons comprising the nigrostriatal pathway. Most PD patients show significant deficiency of gangliosides, including GM1, in the brain, and GM1 gan...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Molecular therapy 2021-10, Vol.29 (10), p.3059-3071
Hauptverfasser:	Itokazu, Yutaka, Fuchigami, Takahiro, Morgan, John C., Yu, Robert K.
Format:	Artikel
Sprache:	eng
Schlagworte:	Administration, Intranasal alpha-synuclein alpha-Synuclein - metabolism Animals Cell Line Disease Models, Animal dopaminergic neuron Down-Regulation Epigenesis, Genetic - drug effects epigenetic regulation G(M1) Ganglioside - administration & dosage G(M1) Ganglioside - pharmacology ganglioside therapy Gangliosides - administration & dosage Gangliosides - pharmacology GD3 ganglioside Gene Expression Regulation - drug effects GM1 ganglioside hualpha-Syn Humans Male Mice mitochondrion nurr1 Original Parkinson Disease - drug therapy Parkinson Disease - genetics Parkinson Disease - metabolism Parkinson's disease Substantia Nigra - drug effects Substantia Nigra - enzymology Tyrosine 3-Monooxygenase - genetics Tyrosine 3-Monooxygenase - metabolism tyrosine hydroxylase
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!